A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.

NCT06523998 | Completed

• 1 other identifier: R023-SABI-00344
• Study Type: observational
• Target: 95
• Locations: 1 country
• Sites: 3

Brief Summary

In Costa Rica there are some descriptive studies of some of these rare infectious diseases (sporotrichosis, chromomycosis and mycetomas); however, there are no recent published reports. Most of the publications on the subject date back to the previous century; from 2000 to the present year there are only publications of small series of cases, so the current behavior of these skin infections is unknown. The primary objective is to analyze the epidemiological, clinical, and therapeutic profile and determine the risk factors in patients with a diagnosis of rare infections of dermatological interest treated at Hospital México, Hospital Rafael Calderón Guardia, and Hospital San Juan de Dios during the period 2019-2023.

Conditions

Sporotrichosis; Chromomycosis; Actinomycosis; Nocardiosis; Mycetoma; Mycobacterial Cutaneous Infection; Coccidioidomycosis; Blastomycosis; Paracoccidioidomycosis; Phaeomycosis

Keywords

Bacterial Infections and Mycoses; Infectious Skin Diseases; Sporotrichosis; Chromoblastomycosis; Mycetoma; Non-tuberculous mycobacteria

Outcome Measures

Primary Outcomes (3)

• Analyze epidemiological, clinical, and therapeutic profile

  Analyze the epidemiological, clinical, and therapeutic profile and determine the risk factors in patients with a diagnosis of rare infections of dermatological interest treated at Hospital México, Hospital Rafael Calderón Guardia, and Hospital San Juan de Dios during the period 2019-2023.

  5 year

• Determine the risk factors

  Analyze the epidemiological, clinical, and therapeutic profile and determine the risk factors in patients with a diagnosis of rare infections of dermatological interest treated at Hospital México, Hospital Rafael Calderón Guardia, and Hospital San Juan de Dios during the period 2019-2023.

  5 year

• Determine the diagnostic methods

  Determine the diagnostic methods utilized for each case, including culture, histological techniques, and molecular testing.

  5 year

Eligibility Criteria

• Age: 18 Years - 120 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients over 18 years with confirmed microbiological, histological and/or molecular diagnosis of sporotrichosis, chromomycosis, actinomycosis, nocardiosis, mycetoma, mycobacterial infection, coccidioidomycosis, blastomycosis, paracoccidioidomycosis, cutaneous nocardiosis and pheomycotic abscess diagnosed and/or treated at Hospital México, Hospital Rafael Calderón Guardia, and Hospital San Juan de Dios during the period 2019-2023.

You may qualify if:

• Age over 18 years, regardless of gender and ethnic group.
• Patients who during the period from January 1, 2019 to December 31, 2023 received medical care at the Hospital Rafael Ángel Calderón Guardia, Hospital México and Hospital San Juan de Dios.
• Subjects who meet a confirmed microbiological, histological and/or molecular diagnosis of sporotrichosis, chromomycosis, actinomycosis, nocardiosis, mycetoma, mycobacterial infection, coccidioidomycosis, blastomycosis, paracoccidioidomycosis, cutaneous nocardiosis and pheomycotic abscess (either through the unique digital health record, pathology registries, clinical laboratory service database of each hospital, clinical laboratory of the University of Costa Rica and Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud).
• Subjects diagnosed at a private level and referred to continue medical care at Hospital Rafael Ángel Calderón Guardia, Hospital México and Hospital San Juan de Dios.

You may not qualify if:

• The research team may exclude patients who have an unconfirmed diagnosis, an erroneous diagnosis, or have participated in the study before, as they may hinder the ability to obtain satisfactory data to achieve the study's objectives.
• Patients who have more than 30% of the variables required for analysis missing will also be excluded from the study.

Sponsors & Collaborators

• Caja Costarricense de Seguro Social: lead

Study Sites (3)

Hospital Rafael Ángel Calderón Guardia

San José, 10101, Costa Rica

Location

Hospital San Juan de Dios

San José, 10103, Costa Rica

Location

Hospital México

San José, 10107, Costa Rica

Location

Related Publications (28)

• Bolognia JL, Schaffer JV, Cerroni L, Callen JP. Dermatología. 4th ed. Barcelona: Elsevier; 2019.

  BACKGROUND

• Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al. Fitzpatrick's Dermatology. 9th ed. New York: McGraw-Hill Education; 2019.

  BACKGROUND

• Trejos A. La cromoblastomicosis como problema micológico [Tesis de grado para optar por el título de licenciatura en Microbiología]. San José, Costa Rica: Universidad de Costa Rica, 1954.

  BACKGROUND

• Trejos A. Cladosporium carrionii n. sp. and the problem of Cladosporia isolated from chromoblastomycosis. Rev Biol Trop. 1954, 2(1):75-112.

  BACKGROUND

• Mora M, Molina B, Moya A. Cromoblastomicosis por Cladophialophora Carrionnii: Primer caso descrito en literatura costarricense. Rev. méd. Costa Rica Centroam. 2010;67(594):373-6.

  BACKGROUND

• Romero A, Trejos A. La cromomicosis en Costa Rica. Rev Biol Trop. 1953;1(2):95-115.

  BACKGROUND

• Soto L, Jaikel D. Cromoblastomicosis: Situación en Costa Rica. Rev. méd. Costa Rica Centroam. 2014;71(613):737-44.

  BACKGROUND

• Salazar K. Esporotricosis y cromoblastomicosis en San Ramón de Costa Rica. Acta Med Costarr. 2022;64(3):1-5. Disponible en https://doi.org/10.51481/amc.v64i3.1224

  BACKGROUND

• Solano E. Cromomicosis. Acta Med Costarr. 1966;9(2):77-85.

  BACKGROUND

• Astorga E, Bonilla E, Martínez C, Mora W. Cromomicosis (Nuevos casos de Cromomicosis tratados con Anfotericina B y 5·Fluorcitosina en forma simultánea). Rev. Méd. de Costa Rica. 1980;47(479):17-22.

  BACKGROUND

• Sáenz L, Morera P. Sobre un caso de blastomicosis suramericana asociada a cromomicosis. Acta Med Costarr. 1963;6(1):55-71.

  BACKGROUND

• Alice E. Ecología de Sporothrix schenkii. Rev Méd de Costa Rica. 1982;49(479):81-6.

  BACKGROUND

• Rodríguez J. Aspectos clínicos, epidemiológicos y ecológicos sobre 100 casos de Esporotricosis en Costa Rica. Revista costarricense de Ciencias Médicas. 1992;12:29-36.

  BACKGROUND

• González J, Rodríguez J. Tres casos de Esporotricosis. Revista costarricense de Ciencias Médicas. 1990;12:57-9.

  BACKGROUND

• Jaramillo O. Esporotricosis en Costa Rica: Estudio clínico epidemiológico y terapéutico de cien casos. Boletín Médico del Seguro Social de Costa Rica. 1972;1(4):27-37.

  BACKGROUND

• Rodríguez J, Gamboa A, Alvarado F. Etiología y epidemiología de los micetomas en Costa Rica. Rev. iberoamer. micol. 1988;5:144-8.

  BACKGROUND

• Trejos A, Romero A. Contribución al estudio de las blastomicosis en Costa Rica. Rev Biol Trop. 1953;1(1):63-81.

  BACKGROUND

• Astorga E, Mora W, Rodríguez A. Tratamiento de la Paracoccidioidomicosis con Ketoconazol (Primer caso en Costa Rica). Rev. Méd. de Costa Rica. 1986;53(494):1-3.

  BACKGROUND

• Fernández K, Quirós JL. Paracoccidiodomicosis: (Reporte de siete casos). Rev. méd. Costa Rica Centroam. 2008;65(582):41-7.

  BACKGROUND

• Kawer A, Madrigal L, Mata F. Paracoccidioidomicosis en lengua. Rev. méd. Costa Rica Centroam. 2011;68(599):505-8.

  BACKGROUND

• Bonilla E, Miranda M, Mata L. Reporte del primer caso de Nocardiasis en Costa Rica. Acta Med Costarr. 1960;3(1):51-5.

  BACKGROUND

• Cueva A. Nocardiosis. Acta Med Costarr. 1968;11(1):45-51. 23.

  BACKGROUND

• CASTRO A, TREJOS A. [Confirmation of the first Central American cas of coccidioidomycosis]. Rev Med Costa Rica. 1951 Apr;18(204):89-90. No abstract available. Undetermined Language.

  PMID: 14854495 BACKGROUND

• Hidalgo W, Xinirachs H, Cappella E, Solano E. Un caso de actinomicosis cervicofacial por Actinomyces bovis. Rev Biol Trop. 1960;8(2):155-63.

  BACKGROUND

• Hidalgo W, Morera P, Hernández VM, Suárez A, Céspedes R. Criptococosis Estudio del primer caso confirmado en Costa Rica. Acta Med Costarr. 1960;3(5):221-35.

  BACKGROUND

• Brizuela S, Montero N. Criptococosis asociado a VIH/SIDA (A propósito de un paciente). Rev. méd. Costa Rica Centroam. 2013;70(605):43-7.

  BACKGROUND

• Mora J, Salazar J, Calderón C, García R. Rinosporidiosis en Costa Rica. (Revisión del tema e informe del primer caso en nuestro país). Acta Med Costarr. 1985;28(2):122-5.

  BACKGROUND

• Riggioni S, Díaz S. Lacaziosis: Micosis cutánea profunda, Reporte de un caso. Rev. clín. esc. med. UCR-HSJD. 2015 Jun 29;5(3). https://doi.org/10.15517/rc_ucr-hsjd.v5i3.19916

  BACKGROUND

MeSH Terms

Conditions

Sporotrichosis; Chromoblastomycosis; Actinomycosis; Nocardia Infections; Mycetoma; Coccidioidomycosis; Blastomycosis; Paracoccidioidomycosis; Phaeohyphomycosis; Bacterial Infections and Mycoses; Skin Diseases, Infectious

Condition Hierarchy (Ancestors)

Dermatomycoses; Mycoses; Infections; Skin Diseases; Skin and Connective Tissue Diseases; Actinomycetales Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Skin Diseases, Bacterial; Lung Diseases, Fungal; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Daniel E Barquero Orias, MD

  Caja Costarricense de Seguro Social

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Doctor

Study Record Dates

• First Submitted: July 23, 2024
• First Posted: July 29, 2024
• Study Start: December 11, 2023
• Primary Completion: May 24, 2024
• Study Completion: May 24, 2024
• Last Updated: July 29, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

CO (3)